AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms
After reading out interim results in mid-November, AstraZeneca has been hot on the heels of Pfizer and Moderna in getting its adenovirus-based vaccine past regulators’ scrutiny. Now, the drugmaker is turning over those data to the public in an effort to speed up its review.
Among patients dosed with AstraZeneca’s Covid-19 vaccine AZD1222, there were no reported hospitalizations or severe cases after 21 days compared with 10 patients hospitalized and two classified as severe in the control arm, according to interim data published Tuesday in The Lancet. There was also one reported death in the control arms of three ongoing studies and none among those receiving a two-dose regimen of AZD1222.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.